MYC and non-small cell lung carcinoma: We found that NSCLC patients with high levels of tumor-associated caspase-4 and c-MyC positive (c-MyC+) (Fig. 3g, black line) had a median survival of 1 year, lower than patients who had lower levels of caspase-4 and c-MyC+ (Fig. 3g, green line; median survival = undefined).